Lenacapavir approved in the US for multidrug resistant HIV

Simon Collins, HIV i-Base

On 22 December 2022, the US FDA approved the capsid inhibitor lenacapavir for multidrug resistant HIV. [1]

Lenacapavir is a long-acting drug given by subcutaneous injection.

It was approved in the EU by the EMA in August 2022, [2]

References

1. Gilead press release Sunlenca (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. (22 December 2022).
   https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv
2. Lenacapavir approved in the EU and UK to treat multidrug resistant HIV. HTB September 2022.
   https://i-base.info/htb/43776

This report was first posted online in December 2022.